Skip to content
DataLookout
Menu

NCT06833320

Propranolol Treatment for Postoperative Chylothorax

StatusRecruiting
PhasePhase 1/2
SponsorJune Wu
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment resumed after suspension Show 4 more changesShow less
    • Eligibility criteria expanded, about 29 words
    • Primary endpoints: details revised at 1 of 7 entries
    • Study description revised
    • Site details revised
  2. Stopped Trial status: Recruiting to Suspended Sponsor's reason: Administrative changes
    • Site details revised
    v6
  3. Minor Study site revisedv5
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 2025 to Sep 9, 2025
    • Site details revised
    v4
  5. Notable Start date: Jun 2025 to Sep 2025v3
  6. Notable Start date: Mar 1, 2025 to Jun 2025
    • Secondary endpoints: details revised at 1 of 16 entries
    v2
  7. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Daily heart rates recorded in flow chart and 1 hour after each dose
Timeframe: 24 days
Daily blood pressures recorded in flow chart and 1 hour after each dose
Timeframe: 24 days
Daily glucose levels
Timeframe: 24 days
Expected and unexpected AEs, per patient
Timeframe: 24 days
Days with documented chest tube (# days), CXR
Timeframe: 24 days
Initial volume of fluid drained (mL, mL/kg/day)
Timeframe: Day 0
Days hospitalized
Timeframe: 6 months

Secondary (16)

Thyroglobulin (TG) lymphocyte count
Pre-operative and post-operative echocardiogram anatomic findings for patients with 4-chamber hearts
Pre-operative and post-operative echocardiogram anatomic findings for patients with single ventricle (SV) physiology
Percent of patients with Type 1 anatomy
Percent of patients with Type 2 anatomy
Show 11 moreShow less
Percent of patients with Type 3 anatomy
Percent of patients with Type 4 anatomy
Serum albumin
White Blood Cell (WBC) count
C-Reactive Protein (CRP)
Immunoglobulin level
AT3 titer
Protein S titer
Protein C titer
Hours on bypass during CHD surgery
Triglyceride level in chylothorax fluid

Arms and interventions

PlaceboPlacebo comparator

Placebo suspension will only have Ora-Blend

Propranolol hydrochlorideActive comparator

Subjects will be randomized to receive 2mg/kg/day. Propranolol will be administered orally, either as a tablet or as a solution, in equal divided doses three times a day.

Drugs: Propranolol Hydrochloride, Placebo

Sites

1 site in 1 country

  • Columbia University Irving Medical Center/NewYork-PresbyterianNew York, New York, United States